Humanized monoclonal antibody directed against the pan-lymphocyte antigen, CD52. Induces complement-mediated cytolysis resulting in lymphocyte depletion. Prepn: L. Riechmann et al., Nature 332, 323 (1988) DOI PubMed; H. Waldmann et al., WO 8907452 (1989 to Medical Research Council); eidem, US 5846534 (1998 to British Technology Group). Structure-activity study: J. Greenwood et al., Eur. J. Immunol. 23, 1098 (1993) DOI PubMed. Crystal structure of the antibody combining site: G. M. T. Cheetham et al., J. Mol. Biol. 284, 85 (1998) DOI PubMed. Clinical evaluation in chronic lymphocytic leukemia: A. Osterborg et al., Br. J. Haematol. 93, 151 (1996) DOI PubMed; in renal transplant patients: R. Calne et al., Transplantation 68, 1613 (1999) DOI PubMed. Clinical trial in early multiple sclerosis: A. J. Coles et al., N. Engl. J. Med. 359, 1786 (2008) DOI PubMed. Review: F. J. Dumont, Curr. Opin. Investig. Drugs 2, 139-160 (2001) PubMed.
Antineoplastic; immunosuppressant.
Antineoplastic; Monoclonal Antibodies; Immunosuppressant